Cardio-Oncology Spotlight: Dr. Tom Nielan Using biomarkers to detect ICI myocarditis

Tomas G. Neilan, MD, MPH discusses the broad spectrum of biomarkers that can be used to detect ICI mediated myocarditis. Dr. Neilan is an Associate Professor of Medicine at Harvard Medical School, a cardiologist at MGH, the director of the Cardio-Oncology Program at MGH and the co-director of the Cardiovascular Imaging Research Center. He holds the Michael and Kathyrn Park Chair in Cardiology. He is a physician scientist and a board-certified cardiologist. He completed his medical school training at University College Dublin Medical School, his clinical training in Internal Medicine and Cardiology at the Mater Hospital in Dublin and repeated his training in Internal Medicine and Cardiology at MGH. He has also competed advanced training in echocardiography at MGH, a clinical and research fellowship in cardiac MRI at BWH, and a Master’s in Public Health at the Harvard School of Public Health. His career has had two major focuses: 1) Understanding how we can improve the cardiovascular care of patients with cancer and 2) The use of advanced imaging to better understand and characterize cardiovascular disease. He has authored or co-authored more than 150 original manuscripts, 40 review articles, has presented over 400 abstracts at international meetings, and has lectured at major national and international meetings. Dr. Neilan has been awarded the “de Gunzburg Family Endowed Scholar in Cardiology”, The Locke Award for excellence in medical education and elected as a Senior Fellow to the Oliver Wendell Holmes Society at Harvard Medical School.